ICM3 monoclonal antibody blocking ICAM-3: U.S phase I safety pharmacology study, single doses of ICM3 in 25 patients.

Icos Corp. (ICOS), Bothell, Wash.

Read the full 52 word article

How to gain access

Continue reading with a
two-week free trial.